Experienced in Alveolar Soft Part Sarcoma

Dr. Ari D. Baron

Hematology | Oncology

Pacific Hematology Oncology Associates

Pacific Hematology Oncology Assoc.

2100 Webster St,

San Francisco, CA

Clinical Trials:Currently Recruiting for 1 Trial

Offers Telehealth

Experienced in Alveolar Soft Part Sarcoma

Pacific Hematology Oncology Associates

Pacific Hematology Oncology Assoc.

2100 Webster St,

San Francisco, CA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ari Baron is a Hematologist and an Oncologist in San Francisco, California. Dr. Baron is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 50 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Oncology

Licenses

Specialist in CA

Hospital Affiliations

California Pacific Medical Center - Mission Bernal

California Pacific Medical Center- Van Ness Campus

Peninsula Medical Center

Novato Community Hospital

California Pacific Medical Ctr-Davies Campus Hosp

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Alignment Health Plan

MEDICARE MAPD
MEDICARE SNP
OTHER MEDICARE
OTHER MEDICARE PART D

Anthem

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE SNP
MEDICARE-MEDICAID PLAN

Humana

HMO
INDEMNITY
POS
PPO

Kaiser Permanente

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER MEDICARE
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

SCAN Health Plan

INSURANCE PLAN
MEDICARE MAPD

Sutter Health

HMO
OTHER COMMERCIAL

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 14 Less Insurance Carriers -

Locations

PACIFIC HEMATOLOGY ONCOLOGY ASSOC.
2100 Webster St, San Francisco, CA 94115

Call: 415-923-3012

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

50 Clinical Trials

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Enrollment Status: Suspended

Publish Date: October 07, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Olaparib, Pembrolizumab

Study Phase: Phase 2

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Trametinib

Study Phase: Phase 2

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug

Study Drugs: Carboplatin, Paclitaxel, Pevonedistat

Study Phase: Phase 2

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Biological

Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b

Study Phase: Phase 3

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Afatinib Dimaleate, Cetuximab

Study Phase: Phase 2/Phase 3

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers

Enrollment Status: Completed

Publish Date: September 15, 2025

Intervention Type: Drug

Study Drug: ZW25 (Zanidatamab)

Study Phase: Phase 2

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Enrollment Status: Active_not_recruiting

Publish Date: August 14, 2025

Intervention Type: Drug

Study Drug: Sotorasib

Study Phase: Phase 2

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Nivolumab

Study Phase: Phase 3

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Enrollment Status: Completed

Publish Date: May 16, 2025

Intervention Type: Other, Drug

Study Drugs: Cisplatin, Veliparib

Study Phase: Phase 2

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 15, 2025

Intervention Type: Drug, Dietary supplement, Biological

Study Drugs: Dexamethasone, Docetaxel, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab

Study Phase: Phase 2/Phase 3

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Enrollment Status: Active_not_recruiting

Publish Date: May 07, 2025

Intervention Type: Drug, Other

Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 2/Phase 3

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Enrollment Status: Active_not_recruiting

Publish Date: March 30, 2025

Intervention Type: Drug

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 19, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2025

Intervention Type: Device, Biological, Other, Drug

Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab

Study Phase: Phase 2

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Enrollment Status: Completed

Publish Date: January 13, 2025

Intervention Type: Procedure, Drug

Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate

Study Phase: Phase 2

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 27, 2024

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

Enrollment Status: Completed

Publish Date: November 22, 2024

Intervention Type: Biological

Study Drug: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody

Study Phase: Phase 1

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Enrollment Status: Completed

Publish Date: November 05, 2024

Intervention Type: Drug

Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX

Study Phase: Phase 3

A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: September 03, 2024

Intervention Type: Drug

Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate

Study Phase: Phase 2

A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Enrollment Status: Completed

Publish Date: September 03, 2024

Intervention Type: Drug, Biological

Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab

Study Phase: Phase 2

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Enrollment Status: Completed

Publish Date: May 03, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Enrollment Status: Completed

Publish Date: April 24, 2024

Intervention Type: Drug, Radiation, Biological

Study Phase: Phase 2

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: February 09, 2024

Intervention Type: Drug

Study Drugs: PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil

Study Phase: Phase 1/Phase 2

Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Enrollment Status: Completed

Publish Date: August 29, 2023

Intervention Type: Drug, Biological

Study Phase: Phase 1/Phase 2

A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)

Enrollment Status: Completed

Publish Date: June 09, 2023

Intervention Type: Biological, Other

Study Drugs: Durvalumab, Tremelimumab

Study Phase: Phase 2

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Enrollment Status: Completed

Publish Date: June 01, 2023

Intervention Type: Biological, Drug, Other

Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML

Enrollment Status: Terminated

Publish Date: February 08, 2023

Intervention Type: Drug

Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim

Study Phase: Phase 3

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

Enrollment Status: Completed

Publish Date: January 20, 2023

Intervention Type: Drug

Study Drug: Ramucirumab

Study Phase: Phase 3

A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas

Enrollment Status: Completed

Publish Date: January 03, 2023

Intervention Type: Drug

Study Drugs: CPI 613, mFolfirinox, Folfirinox

Study Phase: Phase 3

A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: October 19, 2022

Intervention Type: Drug, Procedure

Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation

Study Phase: Phase 2

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

Enrollment Status: Completed

Publish Date: May 27, 2022

Intervention Type: Biological

Study Phase: Phase 2

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Enrollment Status: Unknown

Publish Date: May 24, 2022

Intervention Type: Drug, Procedure, Radiation

Study Drugs: mFOLFIRINOX, FOLFOX

Study Phase: Phase 2

Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

Enrollment Status: Terminated

Publish Date: April 25, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Enrollment Status: Completed

Publish Date: June 23, 2021

Intervention Type: Other, Drug

Study Drug: Talazoparib

Study Phase: Phase 2

A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Enrollment Status: Completed

Publish Date: May 27, 2021

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Palbociclib

Study Phase: Phase 2/Phase 3

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: June 02, 2020

Intervention Type: Drug

Study Phase: Phase 1

View 49 Less Clinical Trials

25 Total Publications

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Journal: JCO precision oncology

Published: October 16, 2025

View All 25 Publications

Similar Doctors

Distinguished in Alveolar Soft Part Sarcoma

Dr. Kristen N. Ganjoo

Oncology

Distinguished in Alveolar Soft Part Sarcoma

Dr. Kristen N. Ganjoo

Oncology

Stanford Health Care

300 Pasteur Dr,

Stanford, CA

(28.4 miles away)

650-723-4000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Kristen Ganjoo is an Oncologist in Stanford, California. Dr. Ganjoo is rated as an Elite provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

Distinguished in Alveolar Soft Part Sarcoma

Dr. Nam Q. Bui

Oncology

Distinguished in Alveolar Soft Part Sarcoma

Dr. Nam Q. Bui

Oncology

Stanford Health Care

300 Pasteur Dr,

Stanford, CA

(28.4 miles away)

650-723-4000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Nam Bui is an Oncologist in Stanford, California. Dr. Bui is rated as an Elite provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Liposarcoma, Gastrointestinal Stromal Tumor, and Tissue Biopsy.

Distinguished in Alveolar Soft Part Sarcoma

Dr. Varun Monga

Hematology Oncology | Oncology

Distinguished in Alveolar Soft Part Sarcoma

Dr. Varun Monga

Hematology Oncology | Oncology

Regents Of The University Of California

505 Parnassus Ave,

San Francisco, CA

(2.4 miles away)

415-476-4029

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Varun Monga is a Hematologist Oncology specialist and an Oncologist in San Francisco, California. Dr. Monga is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Astrocytoma, Embryonal Tumor with Multilayered Rosettes, Gliosarcoma, and Neuroepithelioma.

VIEW MORE ALVEOLAR SOFT PART SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baron's expertise for a condition

ConditionClose